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A 2011 Cochrane Review found that adequately randomized trials sometimes revealed larger, sometimes smaller,
and often similar effect sizes to inadequately randomized trials. However, they found no average statistically
significant difference in effect sizes between the two study types. Yet instead of concluding that adequate
randomization had no effect the review authors postulated the “unpredictability paradox”, which states that
randomized and non-randomized studies differ, but in an unpredictable direction. However, stipulating the
unpredictability paradox is problematic for several reasons: 1) it makes the authors’ conclusion that adequate
randomization makes a difference unfalsifiable—if it turned out that adequately randomized trials had significantly
different average results from inadequately randomized trials the authors could have pooled the results and
concluded that adequate randomization protected against bias; 2) it leaves other authors of reviews with similar
results confused about whether or not to pool results (and hence which conclusions to draw); 3) it discourages
researchers from investigating the conditions under which adequate randomization over- or under-exaggerates
apparent treatment benefits; and 4) it could obscure the relative importance of allocation concealment and blinding
which may be more important than adequate randomization.
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Randomization can reduce selection bias and a variety of
other confounding factors in healthcare trials [1-4]. We
would therefore expect adequately randomized trials to
have different results from inadequately randomized trials.Main text
In spite of the rationale for adequate randomization, dif-
ferences between adequately and inadequately randomized
trials have proven difficult to detect empirically. In 1995,
Schulz and colleagues [1] found that trials using allocation
concealment (concealing which participants are in each
treatment group) and double-blinding yielded smaller
effect sizes, but they found no statistically significant
benefit of adequate over inadequate randomization.
Odgaard-Jensen and colleagues [5] conducted an over-
view of systematic reviews in 2011 in an attempt to pro-
vide more definitive evidence. The review included* Correspondence: jeremy.howick@phc.ox.ac.uk
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article, unless otherwise stated.systematic reviews comparing randomized trials with trials
that used some other, non-random method of assignment
to conditions (such as alternation). Of the seven reviews
eligible for the meta-analysis, six failed to detect a statisti-
cally significant difference between adequately and in-
adequately randomized trials, and one revealed smaller
effects in randomized trials. Three of the six reviews that
failed to detect a statistically significant difference sug-
gested that adequate randomization increased effect sizes,
and three suggested they reduced effect sizes.
Had they pooled the results (which we did, see Figure 1),
they would have reported no statistically significant
difference between the two study types, yet Odgaard-
Jensen and colleagues did not pool the results. Instead
they asserted that the results from randomized and
non-randomized studies differ, but in an unpredictable
direction: “it is not generally possible to predict the
magnitude, or even the direction, of possible selection
biases and consequent distortions of treatment effects
from studies with non-random allocation” [5]. They
called this the “unpredictability paradox”.Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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Figure 1 Pooled results from adequately and inadequately randomized trials in the Odgaard-Jensen and colleagues Cochrane Review
[5]. CI, confidence interval; IV, independent variable; RCT, randomized controlled trial; SD, standard deviation; Std, standardized.
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the “unpredictability paradox” from the observed data.
1. Invoking the unpredictability paradox makes the
conclusions of the Odgaard-Jensen review unfalsifiable
and unscientific (from a Popperian perspective) [6].
If it turned out that randomized trials had average
significantly different average results from
non-randomized studies, the authors could have
pooled the results and concluded that adequately
randomized trials were better. In fact, adequate
randomization did not yield statistically significant
different average results, and the authors drew the
very same conclusion that they could have had the
data indicated differences between adequately and
inadequately randomized trials. Drawing the same
conclusion from conflicting evidence allows us to
make assertions that do not take empirical evidence
into account, which is unscientific in the absence of
further justification.
2. Appeal to the unpredictability paradox reveals an
inconsistent approach with regards to pooling data in
Cochrane Review methodology. When we pooled
the results from the Odgaard-Jensen and colleagues
review we found no statistically significant difference
between randomized and non-randomized trials
(standardized mean difference = −0.17, 95% CI = −0.64
to 0.29; P = 0.47; Figure 1). The decision to pool
appears to justify the inference to the conclusion that
adequate randomization was not a methodological
benefit easy to draw. (As an aside, the problem is
not whether to pool itself, but rather the inference
from the unpooled result to the conclusion of a
difference in an unpredictable direction.) The
Cochrane Handbook recommends not pooling
highly heterogeneous results [7], yet the results of the
Odgaard-Jensen and colleagues review were remarkably
consistent in terms of effect direction, with all but one
included study revealing no statistically significant
difference. Moreover Cochrane Reviews conducted by
the same review group have pooled results with
substantially higher heterogeneity (I2 = 87%) [8]. Theinconsistency in Cochrane methodology was further
highlighted in a recent similar systematic review of
randomized versus observational studies. The authors
of the latter review found similarly heterogeneous
results, but decided to pool and concluded that
randomized and non-randomized studies were not
qualitatively different [9]. Had they adopted the
same strategy as Odgaard-Jensen and colleagues
they could have chosen not to pool, postulated the
“unpredictability paradox” and concluded that
randomized trials have different results from
observational studies, but in an unpredictable
direction.
3. The unpredictability paradox has not been used or
replicated independently [10]. If proposing that the
unpredictability paradox is justified, one would
expect independent research to use and validate it.
This has not been done.
4. Invoking the unpredictability paradox discourages
researchers from investigating the conditions
under which randomization over- and under-
exaggerates apparent treatment benefits. If, indeed,
adequate randomization makes a difference, it
would be interesting to know what made adequate
randomization increase effect size and what made
it decrease effect size. Proposing the unpredictability
paradox as an explanation for the effect of adequate
randomization suggests that there is nothing more
fundamental to be learned about the conditions under
which adequate randomization makes a difference,
precisely because it is unpredictable. This approach
therefore arguably stifles future research in the area.
5. If it turns out that adequate randomization is not a
powerful protection against bias, it could obscure the
relative importance of allocation concealment and
blinding which may be more important.
Discussion
Our arguments presented here do not imply that inad-
equate randomization is acceptable. In fact one of us
has written a book defending the virtues of (adequate)
randomization [11]. We believe it is self-evident that
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and also makes allocation concealment and blinding
more difficult. Allocation concealment and blinding,
in turn, have been shown empirically to reduce bias in
many cases [4,12]. It follows that, when results from
adequately randomized studies and inadequately ran-
domized studies (or observational studies) differ, the
results of the adequately randomized trial is likely to
be closer to the truth (all other things being equal).
Conclusions
Our conclusion is that Odgaard-Jensen and colleagues’
proposed unpredictability paradox requires further justi-
fication. Providing a justification will improve the sound-
ness and validity of the Odgaard-Jensen and colleagues
review, inform debates about when to pool heteroge-
neous results in systematic reviews, rationalize Cochrane
Review methodology, and tell us more about the mech-
anism by which adequate randomization reduces bias.
Critical appraisal tools [13,14], and justification for the
inclusion of studies in systematic reviews may also need
to be revised in light of an eventual justification for the
unpredictability paradox.
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